Eton Pharmaceutical ETON 深 沪
已收盘 08-14 16:00:00 美东时间
58.86
+18.060
+44.26%
华盛通- 最 高59.79
- 今 开54.93
- 成交量 231.79万股
- 最 低 53.01
- 昨 收 40.80
- 总市值 16.12亿
- 52周最高 59.79
- 市盈率 静 --
- 换手率 8.46%
- 52周最低 14.27
- 委 比 -13.86%
- 总股本 2739.24万
- 历史最高 59.79
- 量 比 4.85
- 振 幅 16.62%
- 历史最低 1.95
- 每 手 1
- 风险率 8.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 revenue guidance above estimates.
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY26 revenue guidance above estimates.
08-14 04:22
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $37.568 mill...
08-14 04:09
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Eton Pharmaceuticals Licenses U.S. Rights To Rare Disease Product Candidate ASN-001 From Auson Pharmaceuticals For Treatment Of Proliferating Superficial Infantile Hemangiomas
ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timolol Complementary product to HEMANGEOL® (propranolol hydrochloride) oral solution, positioning Eton, if approved, to treat full spectrum of infantile hemangioma patients...
08-05 18:53
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Eton Pharmaceuticals licensed ASN-001 (timolol topical gel) from Auson Pharmaceuticals to treat moderate infantile hemangiomas. ASN-001 showed 56% and 42% elimination rates at week 24 in Phase II/III trials, compared to 15% for placebo. Eton plans to submit an NDA in 2H 2027 for potential 2028 launch. ASN-001 complements HEMANGEOL, addressing a broader patient population with an estimated 20,000-30,000 annual candidates. The product leverages Eto...
08-05 10:50
Eton Seeks Expanded KHINDIVI Label for Pediatric Use
Eton Pharmaceuticals ( ($ETON) ) has issued an announcement. On July 29, 2026, ...
07-29 19:33
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $62.
07-29 02:01
美股大行评级 | 台积电、联合健康、美国合众银行获多家大行上调目标价；奈飞、直觉外科遭数十家大行下调目标价
今日重点评级关注：摩根大通：维持联合大陆航空"超配"评级，目标价从156美元升至203美元；摩根士丹利：维持联合大陆航空"超配"评级，目标价从185美元升至190美元
07-20 13:49
Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60
Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.
07-17 18:24
